Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COWBOY: Vemurafenib + Cobimetinib Lead-in vs Standard Ipilimumab + Nivolumab in BRAF V600 Melanoma
2016-003279-23Phase 2Active
- Sponsor
- Radboudumc
- Start
- Nov 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of vemurafenib, cobimetinib, nivolumab and ipilimumab in melanoma (2 arms), sponsored by Radboudumc. Primary endpoint: Best overall response rate (BORR) per RECIST 1.1. Started Nov 2019; status: active.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on 2016-003279-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003279-23.